Stockreport

Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20% [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF to their statutory estimates that might leave shareholders a little shell-shocked. Revenue estimates were cut sharply as the analysts signalled a weaker outlook - perhap [Read more]